Name: Relias Media
Price range: $

APIC 2023 Keynote: IPs Must Reclaim Their Power

The 2023 APIC keynote speaker called for infection preventionists to reclaim their narrative, to tell people what they do in no uncertain terms, and to empower others to do likewise.

Infectious Disease Alert Updates

Immunocompromised Patients with Persistent COVID-19; Endemic Mycoses Are No Longer ‘-Demic’

Blastomycosis Outbreak

The largest reported outbreak of blastomycosis has affected at least 115 employees, contractors, or visitors to a paper mill in the Michigan Upper Peninsula.

Healthcare Workers Not Likely Infected, Colonized with C. auris

Recent reports highlighting the continuing increase and geographic spread of Candida auris — a multidrug-resistant fungus that is moving between healthcare facilities — have raised the question of whether healthcare workers could be infected or colonized with the emerging pathogen. It is highly unlikely, but the risk is not zero.

Rezafungin Injection (Rezzayo)

Rezafungin can be prescribed to treat candidemia and invasive candidiasis in patients age 18 years or older with limited or no alternative options.

CDC: Candida auris Spreading at ‘Alarming’ Rate

The agency reported the number of clinical cases has risen each year since 2016, with the worst spike occurring during the 2020-2021 period.

U.S. Endemic Fungal Infection Surveillance

In the United States in 2019, 29,061 cases of coccidioidomycosis were reported, as were 1,124 cases of histoplasmosis and 240 of blastomycosis.

Ibrexafungerp for Vulvovaginal Candidiasis

The authors of a randomized clinical trial compared one day of oral ibrexafungerp with placebo for women with vulvovaginal candidiasis (VVC). They found ibrexafungerp to be safe and effective, with mild diarrhea the most common adverse event. Ibrexafungerp differs mechanistically from azoles and appears to be a promising new treatment for VVC.